3 catalysts running concurrently
1) CXO rerate with LPM adjacent is sure to garner lots of interest.
2) 127m hole assay result next week will sure put another rocket underneath.
3) The maiden mineral resource estimate in October will propel the share price to new height.
Target $1-2 by end of the year.
- Forums
- ASX - By Stock
- Ann: Investor Presentation
3 catalysts running concurrently1) CXO rerate with LPM adjacent...
-
- There are more pages in this discussion • 55 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add LPM (ASX) to my watchlist
|
|||||
Last
14.5¢ |
Change
0.005(3.57%) |
Mkt cap ! $19.18M |
Open | High | Low | Value | Volume |
14.5¢ | 14.5¢ | 14.5¢ | $2.791K | 19.25K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 9250 | 14.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
15.5¢ | 26114 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 9250 | 0.145 |
2 | 25585 | 0.140 |
2 | 11202 | 0.135 |
1 | 50000 | 0.130 |
1 | 15000 | 0.120 |
Price($) | Vol. | No. |
---|---|---|
0.155 | 26114 | 3 |
0.160 | 5702 | 2 |
0.165 | 7601 | 2 |
0.175 | 35000 | 1 |
0.180 | 87080 | 2 |
Last trade - 15.42pm 12/07/2024 (20 minute delay) ? |
Featured News
TLX
Telix jumps 11.6% as US government indicates proposed medicare changes won't affect prostate cancer drug
RNU
Renascor wins a funding boost given it wants to produce a critical mineral – but $5M award pales in comparison to some
LPM (ASX) Chart |